Sohail Hassan, MD
Cardiovascular Disease · Dearborn, MINPI 1225039563
Payments from drug & device makers
Across 918 payments — averaging $322.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$91K
- Impulse Dynamics (USA) Inc.$90K
- Medtronic$39K
- Boston Scientific$33K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$31K
- Biotronik Inc.$7K
- plus $6K from 28 others
Across 1 payment — averaging $200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$200
What the payments were for
- Consulting fees$2,9002%
- Speaking & faculty fees$48,55040%
- Travel & lodging$41,08834%
- Food & beverage$28,17723%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 106 | $91,047 |
| Impulse Dynamics (USA) Inc. | 71 | $89,792 |
| Medtronic(2 entities) | 215 | $38,701 |
| Boston Scientific | 229 | $32,947 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 74 | $30,954 |
| Biotronik Inc. | 34 | $6,916 |
| Biosense Webster, Inc. | 13 | $1,098 |
| Atricure, Inc. | 6 | $841 |
| Johnson & Johnson | 23 | $463 |
| Pfizer | 28 | $438 |
| AstraZeneca | 10 | $431 |
| E.r. Squibb & Sons, L.L.C. | 20 | $339 |
| Boehringer Ingelheim | 13 | $339 |
| Cardiva Medical, Inc. | 11 | $308 |
| Novartis | 20 | $308 |
| Irhythm Technologies, Inc. | 1 | $189 |
| Sanofi-aventis U.S. LLC | 10 | $163 |
| Teleflex LLC | 2 | $154 |
| Philips North America LLC | 2 | $133 |
| Kestra Medical Technology Services, Inc. | 3 | $102 |
| Inari Medical, Inc. | 1 | $102 |
| Novo Nordisk | 4 | $74 |
| Amgen | 5 | $74 |
| Merck | 1 | $62 |
| Baylis Medical Company Inc | 5 | $62 |
| Elutia, Inc. | 2 | $42 |
| Cordis US CORP. | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 1 | $34 |
| Chiesi USA, Inc. | 1 | $27 |
| Terumo Medical Corporation | 1 | $22 |
| Preventice Services, LLC | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$28,509
- OPTIMIZER$22,185
- Reveal LINQ$10,059
- AVEIR$5,318
- Farapulse$4,292
- Micra$2,927
- GENERAL - THERAPIES$2,694
- Arctic Front$1,753
- DiamondTemp$1,576
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$661
- Acticor 7 VR-T DX$492
- AMVIA EDGE$492
- LINQ II$300
- ARCTIC FRONT ADVANCE$260
- Carto 3$245
- EnSite Precision Cardiac Mapping System$233
- FARXIGA$225
- Azure$224
- ZIO XT Patch$189
- ENSITE$182
How this compares
$296,273 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 276 | $320,822 |
| XareltoRivaroxaban | 65 | $86,121 |
| EntrestoSacubitril/Valsartan | 42 | $60,842 |
| JardianceEmpagliflozin | 26 | $33,488 |
| Propafenone Hcl | 221 | $19,416 |
| FarxigaDapagliflozin Propanediol | 15 | $13,855 |
| Dofetilide | 48 | $10,147 |
| Carvedilol | 467 | $8,224 |
| Mexiletine Hcl | 31 | $6,409 |
| Amiodarone Hcl | 174 | $6,039 |
| Metoprolol Succinate | 210 | $4,594 |
| Quinidine Gluconate | 12 | $4,438 |
| Flecainide Acetate | 91 | $4,330 |
| Losartan Potassium | 197 | $3,127 |
| Atorvastatin Calcium | 166 | $2,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $438 | $320,822276 claims |
| Johnson & JohnsonXarelto | $463 | $86,12165 claims |
| NovartisEntresto | $308 | $60,84242 claims |
| Boehringer IngelheimJardiance | $339 | $33,48826 claims |
| AstraZenecaFarxiga | $431 | $13,85515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Dearborn
- Elias KassabDearborn$352K
- Stanley ChetcutiAnn Arbor$4.3M
- Sandeep KhuranaGrandville$2.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
- Vallerie McLaughlinAnn Arbor$1.4M
- Ahmad MizyedYpsilanti$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.